SAB Biotherapeutics (SABSW) Expected to Announce Quarterly Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABSW – Get Free Report) is expected to be releasing its results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.2830) per share and revenue of $0.1250 million for the quarter.

SAB Biotherapeutics Stock Up 29.4%

NASDAQ SABSW opened at $0.02 on Wednesday. The stock’s 50 day moving average is $0.01 and its two-hundred day moving average is $0.02. SAB Biotherapeutics has a 1-year low of $0.00 and a 1-year high of $0.06.

About SAB Biotherapeutics

(Get Free Report)

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.

Read More

• Five stocks we like better than SAB Biotherapeutics
• System Upgrade: First Internet Bancorp Options Surge
• AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
• The AI Chip Blockade Is Creating a Shadow Market
• Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter